Natera Inc (NASDAQ:NTRA) has been given an average recommendation of “Buy” by the eleven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $29.00.
NTRA has been the subject of several analyst reports. BidaskClub cut shares of Natera from a “sell” rating to a “strong sell” rating in a report on Saturday, December 15th. ValuEngine raised shares of Natera from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 15th. Cowen reissued a “buy” rating and set a $30.00 price target on shares of Natera in a report on Friday, November 9th. Finally, Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a report on Tuesday, January 22nd.
Institutional investors have recently modified their holdings of the business. Jennison Associates LLC increased its stake in shares of Natera by 1.8% during the 4th quarter. Jennison Associates LLC now owns 3,706,873 shares of the medical research company’s stock worth $51,748,000 after purchasing an additional 65,025 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Natera by 28.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares in the last quarter. Vanguard Group Inc increased its stake in shares of Natera by 28.9% during the 3rd quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares in the last quarter. BlackRock Inc. increased its stake in shares of Natera by 33.5% during the 3rd quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock worth $66,679,000 after purchasing an additional 698,379 shares in the last quarter. Finally, FMR LLC purchased a new position in shares of Natera during the 3rd quarter worth approximately $59,599,000. 87.50% of the stock is owned by institutional investors.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: Terms to Better Understand Call Options
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.